The prognostic value of D-dimer levels in metastatic osteosarcoma patients treated with second-line chemotherapy

Yujing Huang; Bangjian Liu; Yuanjue Sun; Jianjun Zhang; Yang Yao; Aina He

doi:10.18632/oncotarget.11571

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The prognostic value of D-dimer levels in metastatic osteosarcoma patients treated with second-line chemotherapy

Yujing Huang, Bangjian Liu, Yuanjue Sun, Jianjun Zhang, Yang Yao and Aina He _

PDF | HTML | How to cite

Oncotarget. 2016; 7:65568-65576. https://doi.org/10.18632/oncotarget.11571

Metrics: PDF 2201 views | HTML 2029 views | ?

Abstract

Yujing Huang1,*, Bangjian Liu2,*, Yuanjue Sun1, Jianjun Zhang1, Yang Yao1, Aina He1

1Department of Oncology, Affiliated Sixth People’s Hospital, Shanghai Jiaotong University, 200233 Shanghai, People’s Republic of China

2Department of Neurology, Affiliated Sixth People’s Hospital, Shanghai Jiaotong University, 200233 Shanghai, People’s Republic of China

*These authors have contributed equally to this work

Correspondence to:

Aina He, email: [email protected]

Yang Yao, email: [email protected]

Keywords: D-dimer, osteosarcoma, chemotherapy response, prognosis, second-line chemotherapy

Received: March 15, 2016 Accepted: August 09, 2016 Published: August 24, 2016

ABSTRACT

We performed a retrospective analysis of 32 metastatic osteosarcoma cases to examine the prognostic value of the plasma D-dimer level. We assessed the D-dimer level before second-line chemotherapy (D1) and the D-dimer level after two cycles of second-line chemotherapy (D2). The change in D-dimer level (ΔD) was defined as D2 minus D1. The overall survival (OS) of patients with a high D1 was significantly shorter than those with a low D1 (median OS, 4.7 vs. 16.2 months, P=0.001). Similar results were observed for the D2 (median OS, 4.7 vs. 8.6 months, P=0.033). Multivariable analysis demonstrated that a high D1 (hazard ratio, 3.375; 95% confidence interval, 1.133–10.053; P=0.029) was an unfavorable independent prognostic factor. The mean D2 of 11 patients with stable disease decreased by 0.69 mg/mL compared to the D1 (P = 0.016). The mean D2 increased by 1.47 mg/mL compared to the D1 in 21 patients with progressive disease (P = 0.004). The data suggest that D-dimer may serve as a prognostic biomarker for metastatic osteosarcoma patients treated with second-line chemotherapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11571

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

The prognostic value of D-dimer levels in metastatic osteosarcoma patients treated with second-line chemotherapy

Abstract